Alnylam Swings to Profit on Soaring Product & Collaboration Revenue

Ticker: ALNY · Form: 10-Q · Filed: Oct 30, 2025 · CIK: 1178670

Sentiment: bullish

Topics: Biotechnology, RNAi Therapeutics, Pharmaceuticals, Revenue Growth, Profitability, Drug Development, Commercialization

Related Tickers: ALNY, NVS, REGN

TL;DR

**ALNY's Q3 results are a game-changer, proving their RNAi pipeline is finally delivering serious cash and making them a biotech force to reckon with.**

AI Summary

Alnylam Pharmaceuticals, Inc. (ALNY) reported a significant financial turnaround for the nine months ended September 30, 2025, achieving a net income of $127.3 million, a substantial improvement from a net loss of $194.4 million in the prior year period. This was primarily driven by a robust increase in total revenues, which surged to $2.62 billion from $1.66 billion year-over-year. Net product revenues more than doubled to $1.99 billion from $1.20 billion, and net revenues from collaborations also saw a strong rise to $512.4 million from $403.3 million. Despite increased operating costs, including research and development expenses climbing to $947.6 million from $826.1 million, and selling, general and administrative expenses reaching $885.3 million from $680.2 million, the company managed to achieve income from operations of $369.9 million, reversing a $71.7 million loss. Cash and cash equivalents increased to $1.49 billion from $966.4 million at December 31, 2024, reflecting strong cash flow from operating activities of $360.5 million.

Why It Matters

This strong financial performance signals ALNY's successful transition towards profitability, a critical milestone for a biotech company. The significant increase in product and collaboration revenues demonstrates strong market adoption for its RNAi therapeutics and effective partnership strategies, positioning ALNY as a formidable player in the competitive biopharmaceutical landscape. For investors, this shift from loss to profit, coupled with robust revenue growth, could indicate a more stable and attractive investment, potentially leading to increased shareholder value. Employees and customers benefit from a financially healthy company that can continue to invest in R&D and expand its product offerings, while the broader market sees a validation of RNAi technology's commercial viability.

Risk Assessment

Risk Level: medium — While ALNY achieved profitability, the company still carries substantial liabilities, including $1.04 billion in convertible debt and $1.35 billion in liability related to the sale of future royalties as of September 30, 2025. Additionally, research and development expenses remain high at $947.6 million for the nine months, indicating ongoing significant investment in a competitive and uncertain drug development environment.

Analyst Insight

Investors should consider ALNY's strong revenue growth and shift to profitability as a positive indicator of its commercial strategy's success. However, they should closely monitor the company's substantial debt and ongoing R&D expenditures, as these could impact future financial flexibility and profitability. A deeper dive into product-specific sales trends and pipeline advancements is warranted.

Financial Highlights

debt To Equity
19.73
revenue
$2,616,904,000
operating Margin
14.1%
total Assets
$4,851,662,000
total Debt
$2,389,442,000
net Income
$127,300,000
eps
N/A
gross Margin
70.1%
cash Position
$1,490,249,000
revenue Growth
+58.1%

Revenue Breakdown

SegmentRevenueGrowth
Net product revenues$1,991,832,000+66.6%
Net revenues from collaborations$512,423,000+27.0%
Royalty revenue$112,649,000+99.6%

Key Numbers

Key Players & Entities

FAQ

How did Alnylam's net income change in the nine months ended September 30, 2025?

Alnylam Pharmaceuticals, Inc. reported a net income of $127.3 million for the nine months ended September 30, 2025, a substantial improvement from a net loss of $194.4 million in the same period of 2024.

What were Alnylam's total revenues for the nine months ended September 30, 2025?

Alnylam's total revenues for the nine months ended September 30, 2025, reached $2.62 billion, a significant increase from $1.66 billion reported in the prior year period.

What contributed to Alnylam's revenue growth in Q3 2025?

Revenue growth was primarily driven by net product revenues, which more than doubled to $1.99 billion from $1.20 billion, and increased net revenues from collaborations, rising to $512.4 million from $403.3 million.

How did Alnylam's operating expenses change in the nine months ended September 30, 2025?

Operating costs and expenses increased to $2.25 billion from $1.73 billion. Research and development expenses rose to $947.6 million from $826.1 million, and selling, general and administrative expenses increased to $885.3 million from $680.2 million.

What is Alnylam's cash position as of September 30, 2025?

As of September 30, 2025, Alnylam had cash and cash equivalents of $1.49 billion, up from $966.4 million at December 31, 2024.

Did Alnylam generate positive cash flow from operations in the nine months ended September 30, 2025?

Yes, Alnylam generated $360.5 million in net cash from operating activities for the nine months ended September 30, 2025, a significant improvement from $86.4 million in the prior year.

What are some key liabilities for Alnylam as of September 30, 2025?

Key liabilities include $1.04 billion in convertible debt and $1.35 billion in liability related to the sale of future royalties, indicating significant financial obligations.

What is Alnylam's strategy for becoming a top-tier biotech company?

Alnylam aims to achieve its Alnylam P5x25 strategy, which includes becoming a top-tier biotech company by the end of 2025 and achieving sustainable operating profitability beginning in 2025.

What are the primary risks Alnylam faces in its business operations?

Alnylam faces risks related to obtaining and maintaining regulatory approvals, market size and commercialization success of its products, progress of R&D programs, competition from other products, and the impact of healthcare reforms.

How many shares of common stock did Alnylam have outstanding as of October 24, 2025?

As of October 24, 2025, Alnylam Pharmaceuticals, Inc. had 132,113,818 shares of Common Stock, $0.01 par value per share, outstanding.

Risk Factors

Industry Context

Alnylam Pharmaceuticals operates in the highly competitive and innovative biopharmaceutical sector, specifically focusing on RNA interference (RNAi) therapeutics. The industry is characterized by significant R&D investment, long development cycles, and stringent regulatory oversight. Key trends include the increasing demand for novel treatments for rare and genetic diseases, advancements in gene silencing technologies, and strategic partnerships to accelerate drug development and commercialization.

Regulatory Implications

Alnylam's operations are subject to extensive regulatory scrutiny by bodies like the FDA. Successful drug development, clinical trials, and manufacturing processes are critical for market approval and ongoing compliance. Any delays, failures in trials, or manufacturing issues can lead to significant financial and reputational damage.

What Investors Should Do

  1. Monitor R&D pipeline progress and clinical trial results.
  2. Analyze the impact of increasing operating expenses on profitability.
  3. Assess the management of significant debt and derivative liabilities.
  4. Evaluate market penetration and competitive positioning of key products.

Glossary

Accumulated deficit
The total net losses of a company since its inception, minus any net profits. It represents the cumulative losses that have not been offset by profits. (Alnylam has a significant accumulated deficit of $7,160,420,000, indicating that historically, the company has incurred more losses than profits, which is common for biotech firms investing heavily in R&D.)
Development derivative liability
A financial instrument whose value is derived from the outcome of future development activities, often related to milestone payments or contingent obligations in collaborations. (This liability, totaling $560,910,000 (current and non-current), reflects potential future payments tied to the success of its drug development programs.)
Liability related to the sale of future royalties
An obligation arising from an agreement where the company has sold the rights to receive future royalty payments in exchange for upfront capital. (Alnylam has a substantial liability of $1,464,857,000 (current and non-current) related to these sales, representing future payments it is obligated to make.)
Operating lease right-of-use assets
An asset recognized under accounting standards for leases, representing the lessee's right to use an underlying asset for the lease term. (These assets, valued at $191,390,000, represent the company's long-term usage rights for leased properties or equipment.)
Convertible debt
A type of bond or debt security that can be converted into a predetermined amount of the issuer's equity at certain times during the bond's life. (Alnylam has $1,040,276,000 in convertible debt, which presents a potential dilution risk for shareholders if converted.)

Year-Over-Year Comparison

For the nine months ended September 30, 2025, Alnylam Pharmaceuticals has demonstrated a remarkable financial turnaround compared to the same period in 2024. Total revenues surged by 58.1% to $2.62 billion, driven by a more than doubling of net product revenues to $1.99 billion. This top-line growth, coupled with improved operational efficiency, led to a swing from a net loss of $194.4 million to a net income of $127.3 million. Despite increased operating costs in R&D and SG&A, the company achieved positive income from operations, reversing a prior year loss. Cash and cash equivalents also saw a substantial increase, reflecting strong operating cash flow.

Filing Stats: 4,495 words · 18 min read · ~15 pages · Grade level 20 · Accepted 2025-10-30 08:16:06

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS (UNAUDITED)

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED) CONDENSED CONSOLIDATED BALANCE SHEETS AS OF S EPTEMBER 30, 2025 AND DECEMBER 31, 202 4 5 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME ( LOSS ) FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 202 4 6 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024 , THE THREE MONTHS ENDED JUNE 30, 2025 AND 2024, AND THE THREE MONTHS ENDED MARCH 31. 2025 AND 2024 7 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 202 4 9 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 10

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 29

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 42

CONTROLS AND PROCEDURES

ITEM 4. CONTROLS AND PROCEDURES 42

OTHER INFORMATION

PART II. OTHER INFORMATION

LEGAL PROCEEDINGS

ITEM 1. LEGAL PROCEEDINGS 43

RISK FACTORS

ITEM 1A. RISK FACTORS 43

OTHER INFORMATION

ITEM 5. OTHER INFORMATION 79

EXHIBITS

ITEM 6. EXHIBITS 80

SIGNATURES

SIGNATURES 81 "Alnylam," AMVUTTRA , ONPATTRO , GIVLAARI and OXLUMO are registered trademarks of Alnylam Pharmaceuticals, Inc. Our logo, trademarks and service marks are property of Alnylam. All other trademarks or service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective holders. 2 Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of complying with those safe harbor provisions. All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: our views with respect to the potential for our approved and investigational RNAi therapeutics and those of our collaborators, including AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO, Leqvio (inclisiran), Qfitlia (fitusiran), zilebesiran, mivelsiran, nucresiran and cemdisiran; our plans for additional global regulatory filings and the continuing product launches of AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO and our collaborators' plans with respect to Leqvio, Qfitlia and cemdisiran; our ability to obtain regulatory approval of AMVUTTRA (vutrisiran) for the treatment of ATTR amyloidosis with cardiomy

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS ( UNAUDITED )

ITEM 1. FINANCIAL STATEMENTS ( UNAUDITED ) ALNYLAM PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except per share amounts) (Unaudited) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 1,490,249 $ 966,428 Marketable debt securities 1,234,375 1,719,920 Marketable equity securities — 8,156 Accounts receivable, net 964,768 405,308 Inventory 75,383 78,509 Prepaid expenses and other current assets 188,036 116,964 Total current assets 3,952,811 3,295,285 Property, plant and equipment, net 501,754 502,784 Operating lease right-of-use assets 191,390 191,148 Deferred tax assets 98,558 116,863 Restricted investments 51,314 68,593 Other assets 55,835 65,310 Total assets $ 4,851,662 $ 4,239,983 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 117,591 $ 88,415 Accrued expenses 1,153,648 793,692 Operating lease liabilities 44,755 41,886 Deferred revenue 2,541 55,481 Liability related to the sale of future royalties 115,691 113,018 Development derivative liability 121,251 93,780 Total current liabilities 1,555,477 1,186,272 Operating lease liabilities, net of current portion 223,421 229,541 Convertible debt 1,040,276 1,024,621 Liability related to the sale of future royalties, net of current portion 1,349,166 1,334,353 Development derivative liability, net of current portion 439,659 393,139 Other liabilities 9,769 4,969 Total liabilities 4,617,768 4,172,895 Commitments and contingencies (Note 13) Stockholders' equity: Preferred stock, $ 0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of September 30, 2025 and December 31, 2024 — — Common stock, $ 0.01 par value per share, 250,000 shares authorized; 131,791 shares issued and outstanding as of September 30, 2025; 129,294 shares issued and outstanding as of December 31, 2024 1,318 1,293 Additional paid-in capital 7,414,771 7,388,061 Accumulated oth

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing